- Capital Cube•2 months ago
Click here to see latest analysisMediciNova, Inc. reports financial results for the quarter ended March 31, 2016.AnalysisSummary numbers: Revenues of USD 0 million, Net Earnings of USD -3.38 million.The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless.MNOV-US‘s earnings and EBITDA are both […] (Read more...) The post MediciNova, Inc. :MNOV-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 appeared first on CapitalCube.
- Zacks Small Cap Research•3 months ago
On April 20, 2016, Dr. Benjamin Brooks presented interim data from the Phase 2 clinical trial of MN-166 in patients with amyotrophic lateral sclerosis (ALS) at the American Academy of Neurology (AAN) 2016 Annual Meeting. The preliminary data analysis was conducted on 25 patients (20 on MN-166 + riluzole, 5 on placebo + riluzole) that had completed the six-month double blind portion of the study. MN-166 is an anti-inflammatory drug that has been used for more than 20 years in Japan to treat asthma (Rolan et al., 2009) and post-stroke dizziness.
After hours: 6.090.00 (0.00%) as of 4:42 PM EDT
|Bid||5.19 x 100|
|Ask||306.00 x 2500|
|52wk Range||2.62 - 10.16|
|Day's Range||6.01 - 6.16|
|Avg Vol (3m)||170,931|
As of 4:00 PM EDT. Market closed.